Editor in chief’s reply to Ebrahim and Davey Smith

4 Because new guidance in the US and the UK proposes that their use be extended to large numbers of healthy people, 5 6 which has created international controversy about the true balance of benefits and harms in people at low risk of heart disease, 7 and because, in my experience, when the IPD, CSRs...

Full description

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2016-10, Vol.355, p.i5458-i5458
Main Author: Godlee, Fiona
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular disease
Statins
Task forces
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:4 Because new guidance in the US and the UK proposes that their use be extended to large numbers of healthy people, 5 6 which has created international controversy about the true balance of benefits and harms in people at low risk of heart disease, 7 and because, in my experience, when the IPD, CSRs, and other regulatory documents are scrutinised by fresh expert eyes, new and useful information emerges that can better guide patients and doctors in their decisions, as well as informing future research. 8 I am sceptical about the wisdom of medicating large numbers of healthy people, especially when alternatives to drug treatment exist. 9 I hope you will put yourselves forward as one of the groups willing to review the anonymised IPD and other materials when they are made available.
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj.i5458